Improving the diagnosis
and treatment of
cancer and other diseases

So your online presence really delivers at each step

Learn more

Who we are

INOVIQ Ltd (ASX:IIQ) is developing and commercialising an innovative portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers.

Who we are

INOVIQ Ltd (ASX:IIQ) is developing and commercialising an innovative portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers.

Latest ASX Announcements

...

Investor Presentations

...

Share Price

ASX:

Our Technologies

INOVIQ owns or licences the proprietary SubB2M™, NETs, BARD1 and hTERT technologies that have multiple potential diagnostic and therapeutic applications.

Our Products

INOVIQ has commercialised two products including the hTERT test for use as an adjunct to urine cytology testing for bladder cancer and the EXO-NET® pan-exosome capture tool for research purposes.

Pipeline

INOVIQ is developing a multi-product diagnostic and exosome-based pipeline focused on the detection and monitoring of cancer and other diseases to improve patient health outcomes.

Subscribe To
Email Alerts